VSC Stock Overview
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
4SC AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.88 |
| 52 Week High | €18.10 |
| 52 Week Low | €2.96 |
| Beta | 1.69 |
| 1 Month Change | 2.07% |
| 3 Month Change | 2.07% |
| 1 Year Change | 122.00% |
| 3 Year Change | 7.64% |
| 5 Year Change | -47.92% |
| Change since IPO | -91.96% |
Recent News & Updates
Shareholder Returns
| VSC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.2% | -1.2% | 1.7% |
| 1Y | 122.0% | -23.0% | 2.3% |
Price Volatility
| VSC volatility | |
|---|---|
| VSC Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VSC has not had significant price volatility in the past 3 months.
Volatility Over Time: VSC's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 13 | Jason Loveridge | www.4sc.com |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies.
4SC AG Fundamentals Summary
| VSC fundamental statistics | |
|---|---|
| Market cap | €83.14m |
| Earnings (TTM) | -€8.24m |
| Revenue (TTM) | €304.00k |
295.4x
P/S Ratio-10.9x
P/E RatioIs VSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSC income statement (TTM) | |
|---|---|
| Revenue | €304.00k |
| Cost of Revenue | €95.00k |
| Gross Profit | €209.00k |
| Other Expenses | €8.45m |
| Earnings | -€8.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 68.75% |
| Net Profit Margin | -2,709.54% |
| Debt/Equity Ratio | 61.4% |
How did VSC perform over the long term?
See historical performance and comparison